**Qdata® Thyroid Eye Disease (TED) unlocks real-world learnings such as severity and clinical activity for this clinically-validated population that can't be found anywhere else.**

Verana Health® delivers meaningful insights by ingesting, curating and analyzing real-world data from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) and linking it with other data sources such as claims and ophthalmic images.

- ✓ **Exclusive Thyroid Eye Disease Insights**
  Only found here

- ✓ **Uniquely Identified Patient Cohort**
  TED patients are identified by mining EHR notes

- ✓ **Detailed View of Disease Activity and Severity**
  Including designation of TED severity and clinical activity score

## Total in Qdata Thyroid Eye Disease:

**376K+**
De-identified unique patients*

**140K+**
Subset: Unique patients w/ confirmed TED diagnosis via clinical notes

**3.9**
Median length of follow up

*Includes patients who are 18+ years old and have 1+ ICD-10-CM indicating Graves' disease, Hashimoto's disease or Thyrotoxicosis OR 1+ SNOMED-CT for TED OR 1+ clinical note with mention of teprotumumab/Tepezza OR 1+ clinical note with keywords for TED between January 2016 and July 2025.

## Clinical Activity Score (CAS)  Derived from clinical notes in the IRIS Registry

| Variable | Unique Patients with CAS Captured: |
|---|---|
| In Qdata Thyroid Eye Disease | 14,990 |
| In Qdata Thyroid Eye Disease with Confirmed TED Diagnosis & 1+ CAS | 12,380 |
| In Qdata Thyroid Eye Disease with Confirmed TED Diagnosis & 2+ CAS | 6,480 |

*Additional Variables in Development from Unstructured Clinical Notes: Disease Severity (e.g., mild, moderate-to-severe, and sight-threatening) Proptosis Measurements*

# Total in Qdata Thyroid Eye Disease:

### Patient Current Age



- 18-29: 5.8%
- 30-39: 9.5%
- 40-49: 13.7%
- 50-59: 20.5%
- 60-69: 25.9%
- 70-79: 17.7%
- 80-89: 6.9%

### Patient Documented Gender



- Male: 23.4%
- Female: 76.6%

### Patient Ethnicity



- Hispanic: 5.2%
- Not: 59.2%
- Unknow: 35.6%

### Patient Race



- Asian: 2.7%
- Black or: 8.1%
- Other: 8.4%
- White: 56.4%
- Unknown: 24.4%

## Qdata. Thyroid Eye Disease

### Potential Applications:


**Clinical Development**


**HEOR & Medical Affairs**


**Commercialization**

## Ways to Engage Us

- Intuitive Dashboards
- Custom Insights via Services
- Direct Data Access

\* Data current to **July** 2025. Data counts represented are subject to change.
*Data counts for research purposes are dependent on project scope and feasibility.*



## Want to learn more?
Talk to a team member today
team@veranahealth.com

[veranahealth.com/ophthal-request](veranahealth.com/ophthal-request)

### About Verana Health
Verana Health® is revolutionizing patient care and clinical research by unlocking the potential of real-world data. Verana Health has an exclusive real-world data network of 90 million de-identified patients from more than 20,000 clinicians, stemming from its exclusive data partnerships with leading medical societies. Verana Health harnesses deep expertise, secure advanced technology, and direct access to exclusive, near real-time data sources to deliver actionable quality insights that help companies make sense of the data.

For more information, visit www.veranahealth.com